Off-the-Shelf Immune Effector Cells for Hematological Malignancies

Medicine & Life Sciences

1. Stem Cell Transplantation 100%
2. Fetal Blood 73%
3. Hematopoietic Stem Cells 67%
4. Transplants 52%
5. Cell- and Tissue-Based Therapy 40%
6. Natural Killer Cells 38%
7. Chimeric Antigen Receptors 32%
8. Hematopoietic Stem Cell Transplantation 25%
9. Leukemia 25%
10. Stem Cells 24%
11. Graft vs Host Disease 23%
12. Clinical Trials 22%
13. Hematologic Neoplasms 19%
14. Transplantation 18%
15. Immune Reconstitution 16%
16. Cell Self Renewal 14%
17. Recurrence 13%
18. Neoplasms 13%
19. Hematopoiesis 12%
20. Regulatory T-Lymphocytes 12%
21. T-Lymphocytes 11%
22. Genes 10%
23. In Vitro Techniques 10%
24. Adoptive Immunotherapy 10%
25. Bone Marrow 10%
26. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10%
27. Safety 9%
28. Population 9%
29. Zebrafish 8%
30. Multiple Myeloma 7%
31. Allogeneic Cells 7%
32. Therapeutics 7%
33. Epithelial Cells 6%
34. Cell Biology 6%
35. Autografts 6%
36. Blood Cells 6%
37. B-Lymphocytes 6%
38. Clinical Studies 6%
39. Biostatistics 5%
40. Cell Tracking 5%
41. Pluripotent Stem Cells 5%
42. Adoptive Transfer 5%
43. T-Cell Leukemia 5%
44. Sheep 5%
45. Maintenance 5%
46. Heparitin Sulfate 5%
47. Hematopoietic System 5%
48. Cell Transplantation 5%
49. Genetic Techniques 5%
50. Immune System Diseases 5%